#South Korea #Seoul #Seegene #CURECA #STAgora

Seegene Launches STAgora at ESCMID Global 2026

Seegene, a leading global player in molecular diagnostics, recently made waves at the ESCMID Global 2026 event held in Munich, Germany. From April 17 to 21, the company highlighted its pioneering platform, STAgora™, designed for real-time data analysis based on aggregated test statistics. It was showcased alongside an enhanced model of its automated PCR workflow system, CURECA™.

The Seegene booth attracted significant interest from health professionals, laboratory specialists, and industry stakeholders worldwide. Attendees engaged in live demonstrations of the automated PCR workflow at the CURECA station. They participated in discussions about its potential applications while at the STAgora station, where they experienced interactive simulations that showcased the platform's intuitive interface and data visualization capabilities.

At the congress, Seegene’s core message, "From Numbers to Insights," emphasized the importance of integrating automated testing infrastructures with real-time data analytics. Young Seag Baeg, New Business Officer at Seegene, explained, "STAgora is designed to connect PCR test data generated globally to provide clearer insights into the trends of infectious diseases based on aggregated statistics."

This aligns well with the ever-evolving landscape of healthcare, where data-driven insights can guide public health decisions and help understand complex infection patterns. Seegene’s STAgora allows for real-time monitoring of testing results aggregated to present comprehensive data on infection trends, positivity rates, and co-infection patterns.

During the event, healthcare professionals were particularly impressed by the ability to visualize regional infection trends alongside summarized test results, offering them a better grasp of current health challenges.

Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, stated, "There has been a strong interest in STAgora's data processing capabilities and its practical applications." He underscored the company’s dedication to expanding pilot programs and collaborative evaluations with healthcare institutions and laboratories to further assess the platform's effectiveness and pave the way for its future adoption.

Seegene also presented an enhanced model of its CURECA system, inviting visitors to explore its modular construction and the fully automated workflow that integrates all phases of testing—from pre-analytical processes, nucleic acid extraction, to amplification and result processing. Discussions among participants revealed a deep interest in the system's architecture and its real-world applicability in laboratory settings.

A clinician from a German university hospital who attended the STAgora demonstration remarked that the platform offers a more intuitive way to explore and visualize aggregate test data trends. This powerful tool is seen as significant in shaping future clinical decisions.

Seegene had previously introduced STAgora and CURECA at various global diagnostic community conferences, such as ADLM and ESCMID Global 2025. At this year's event, they expanded their booth to allow visitors to interact fully with the STAgora platform, including an interactive touchscreen demonstration area.

In addition to presenting their technologies, Seegene has been engaging with international partners and leading laboratories regarding the adoption and validation of STAgora and CURECA. They organized specialized sessions aimed at health professionals, particularly in Europe, to discuss practical applications and use cases of their technologies.

Looking ahead, Seegene aims to deepen collaboration with clinical, academic, and research partners to bolster the implementation and validation of their data-driven diagnostic platforms. This initiative is part of the company's broader goal to enhance global readiness for infectious diseases through improved diagnostic accessibility and innovation.

About Seegene

Seegene is a world-renowned molecular diagnostics company with over 25 years of experience in research, development, and manufacturing of syndromic real-time PCR technologies. The company has gained acclaim for its proprietary multiplex PCR technology, allowing simultaneous detection of multiple pathogens in a single test.

A standout feature of Seegene’s real-time syndromic PCR technology is its capacity to identify up to 14 pathogens responsible for similar signs and symptoms using a single test tube, delivering quantitative information to support faster and more efficient clinical decision-making. Seegene’s technological prowess became especially pronounced during the COVID-19 pandemic, during which the firm supplied over 340 million tests to more than 100 countries globally.

Capitalizing on its molecular diagnostics expertise, Seegene is expanding beyond single-test diagnostics, developing an integrated diagnostic ecosystem. Among its latest innovations are STAgora™, a real-time diagnostic data analysis platform, and CURECA™, a fully automated PCR system designed to optimize the entire diagnostic workflow. Through its Technology Sharing Initiative and global partnerships, Seegene is committed to broadening access to molecular diagnostics technologies and enhancing global preparedness against infectious diseases.